What is it about?
COVID-19 possible use of Il-6 trans-signaling inhibitor, SGP130Fc
Featured Image
Photo by CDC on Unsplash
Why is it important?
Possible better option then Tocilizumab
Read the Original
This page is a summary of: SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc, Cytokine X, June 2020, Elsevier,
DOI: 10.1016/j.cytox.2020.100029.
You can read the full text:
Contributors
The following have contributed to this page
